MétaCan
Menu
Back to cohort
Record W4387270238 · doi:10.1161/atvb.43.suppl_1.706

Abstract 706: The Development Of New Therapies Targeting Pneumonia-accelerated Atherosclerosis

2023· article· en· W4387270238 on OpenAlexaff
Cameron Stotts, Adil Rasheed, Michèle Geoffrion, Jonathon Salazar Leon, Nancy Simon, Leah C. Susser, My-Anh Nguyen, Suresh Gadde, Katey J. Rayner

Bibliographic record

VenueArteriosclerosis Thrombosis and Vascular Biology · 2023
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Lipids, and Metabolism
Canadian institutionsOttawa Heart InstituteUniversity of Ottawa
Fundersnot available
KeywordsInflammationPneumoniaMedicineLungImmunologyPopulationEicosapentaenoic acidInternal medicineBiologyFatty acidPolyunsaturated fatty acidBiochemistry

Abstract

fetched live from OpenAlex

Background/Objectives: Pneumonia is inflammation of the lungs caused by an infection. Recent studies show an association between pneumonia and an increased risk of a heart attack. This is likely caused by the persistent inflammatory burden in the lungs and arterial vasculature even 30-45 days after clearance of the infection. Therefore, as inflammation is a strong contributor to the progression of atherosclerosis, there is a need to address the persistent inflammatory burden in this patient population. A normal course of inflammation begins with an initial pro-inflammatory phase and ends with a resolution phase, which is marked by tissue return to homeostasis. During pneumonia, resolution pathways are impaired. Returning resolution processes to normal functioning may prove to be an effective strategy to attenuate prolonged pneumonia-associated inflammation. Resolution pathways are mediated by fatty acid derivatives termed specialized pro-resolving lipid mediators (SPMs), the metabolites of poly-unsaturated fatty acids such as eicosapentaenoic acid (EPA). To improve the therapeutic impact, EPA can be encapsulated in nanoparticle carriers to increase bioavailability and therapeutic delivery. We hypothesize that delivery of EPA nanoparticles into the lungs will control the persistent inflammatory response following pneumonia and reduce atherosclerotic burden. Results: Bone-marrow derived macrophages (mouse) stimulated with gram-positive toxins and EPA-nanoparticles demonstrated reduced expression of pro-inflammatory markers measured using ELISA. We have also developed a mouse model of atherosclerosis combined with S. pneumoniae lung infection. Without EPA administration, S.pneumoniae infection followed by 8 weeks on a high fat diet resulted in a trend towards increased plaque size and lesion lipid content. We are currently evaluating if our EPA-nanoparticles promote resolution processes in the S.pneumoniae mouse model. Clinical Impact: We believe that promotion of resolution pathways via increasing SPM production will prove to be an effective strategy to address inflammation during pneumonia while reducing the risk of suppressive effects on the immune system often caused by currently prescribed anti-inflammatories.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.008
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0080.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.293
Teacher spread0.239 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueArteriosclerosis Thrombosis and Vascular BiologySame topicCancer, Lipids, and MetabolismFrench-language works237,207